TAMPA, FLA., Mar 23, 2026 - (ACN Newswire via SeaPRwire.com) - Wellgistics Health, Inc. ("Wellgistics" or the "Company") (NASDAQ:WGRX) today announced that it has entered into a non-exclusive, non-binding Letter of Intent ("LOI") to evaluate a potential acquisition of Neuritek Therapeutics, a neuroscience-focused research organization.The proposed all stock transaction, if completed, is intended to enhance Wellgistics' existing revenue-generating healthcare platform by expanding capabilities adjacent to its core technology-enabled pharmacy distribution and services business. Through its integrated ecosystem spanning prescription fulfillment, wholesale distribution, and AI-driven patient access solutions, Wellgistics connects manufacturers, providers, and a nationwide network of independent pharmacies. The Company believes that adding a research-focused organization could strengthen alignment between drug development and commercialization, enabling earlier engagement with pharmaceutical partners, improving pipeline visibility, and supporting incremental revenue opportunities while enhancing long-term shareholder value through a more integrated and differentiated platform.The transaction remains subject to the completion of due diligence, negotiation and execution of definitive agreements, approval by the boards of directors of the respective parties, and other customary closing conditions. There can be no assurance that a definitive agreement will be entered into or that the proposed transaction will be consummated on the terms currently contemplated, or at all. The LOI is non-binding and does not obligate either party to complete the proposed transaction. The scope, structure, and terms of any potential transaction remain under evaluation and may change materially as a result of ongoing diligence and negotiations.The Company is also actively evaluating additional strategic opportunities across the healthcare and life science sectors as part of its broader growth strategy. These opportunities may include acquisitions, partnerships, or other strategic transactions. There can be no assurance that any such initiatives will result in completed transactions.About Wellgistics Health, IncWellgistics Health is a rapidly scaling, technology-driven healthcare platform positioned at the center of pharmaceutical distribution and patient access. The Company has built an integrated, high-performance ecosystem spanning wholesale distribution, prescription fulfillment, and AI-powered access solutions, directly connecting pharmaceutical manufacturers, healthcare providers, and a nationwide network of independent pharmacies.By combining infrastructure, data, and intelligent automation, Wellgistics is executing on a capital-efficient model designed to capture significant share in large and fragmented healthcare markets. The Company is focused on expanding high-margin revenue streams, deepening strategic manufacturer relationships, and driving operating leverage across its platform. With a differentiated end-to-end offering and disciplined execution, Wellgistics is positioned to accelerate growth, enhance earnings visibility, and deliver outsized long-term value for shareholders.About Neuritek Therapeutics Inc.Neuritek Therapeutics Inc. has developed a next-generation bio-mechanism based treatment, treating the root cause of Post-Traumatic Stress Disorder (PTSD). Neuritek's first to market treatment is an orally active inhibitor of fatty acid amide hydrolase type 1 (FAAH1), the enzyme responsible for metabolizing anandamide (AEA) and the first mechanisms-based treatment for PTSD. The company was founded by Doctor William Hapworth MD., a pioneer in clinical research and a practicing psychiatrist with over 30 years' experience.Learn more at www.neuritek.com or join the conversation at LinkedIn, neuritek-therapeutics-incForward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other applicable federal securities laws. These forward-looking statements include, without limitation, statements regarding: the potential acquisition of Neuritek Therapeutics, Inc. ("Neuritek"), including the anticipated structure, valuation, timing, and likelihood of completion of any transaction; the preliminary and non-binding nature of the letter of intent; the potential strategic, operational, and financial benefits of any such transaction; the Company's ability to negotiate and enter into definitive agreements; the Company's ability to obtain any required financing; the integration of any acquired business; and the Company's broader growth strategy and future performance.Forward-looking statements may be identified by words such as "may," "could," "would," "should," "expect," "anticipate," "believe," "intend," "plan," "project," "estimate," "potential," "opportunity," "target," "forecast," "continue," "will," and similar expressions.These forward-looking statements are based on current expectations, assumptions, and estimates and are subject to significant risks and uncertainties, many of which are beyond the Company's control. Important factors that could cause actual results to differ materially include, but are not limited to: the risk that the parties do not enter into definitive agreements; the risk that the letter of intent is terminated or does not result in a completed transaction; uncertainties related to the preliminary nature of the proposed valuation and transaction terms, which may change materially; the risk that any required financing is not obtained on acceptable terms or at all; the risk that anticipated benefits of any transaction are not realized; risks associated with integrating a research-focused organization into the Company's existing business; risks related to the development, testing, regulatory approval, and commercialization of pharmaceutical or therapeutic products, including the possibility of unfavorable clinical results or delays; regulatory and compliance risks; and other risks and uncertainties described from time to time in the Company's filings with the U.S. Securities and Exchange Commission.Forward-looking statements speak only as of the date they are made, and undue reliance should not be placed on such statements. The Company undertakes no obligation to update or revise any forward-looking statements, except as required by applicable law.Wellgistics Media & Investor ContactMedia: media@wellgisticshealth.comInvestor Relations: IR@wellgisticshealth.comSOURCE: Wellgistics Health, Inc. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

坦帕, 2026年3月23日 - (亞太商訊 via SeaPRwire.com) - Wellgistics Health, Inc.（「Wellgistics」或「本公司」）（納斯達克代碼：WGRX）今日宣布，已簽署一份非獨家且不具約束力的意向書（「LOI」），以評估潛在收購專注於神經科學研究的機構Neuritek Therapeutics。若這項擬議的全股票交易得以完成，旨在透過擴展其核心技術驅動的藥品分銷及服務業務周邊能力，強化 Wellgistics 現有的營收型醫療保健平台。透過涵蓋處方藥配送、批發分銷及 AI 驅動的患者用藥解決方案的整合生態系統，Wellgistics 串聯了製造商、醫療服務提供者以及遍布全國的獨立藥房網絡。本公司認為，納入一家以研究為導向的組織，將能強化藥物開發與商業化之間的協同效應，使公司得以更早與製藥合作夥伴建立聯繫、提升產品管線的透明度，並創造額外的營收機會；同時透過更整合且具差異化的平台，提升長期股東價值。本交易仍須待盡職調查完成、最終協議的協商與簽署、各方董事會批准，以及其他慣常的交割條件達成後，方能生效。無法保證雙方將簽訂最終協議，亦無法保證擬議交易將按目前預期的條款完成，甚至可能無法完成。該意向書不具約束力，亦不強制任何一方完成擬議交易。任何潛在交易的範圍、結構及條款仍在評估中，並可能因持續進行的盡職調查及協商而發生重大變更。作為更廣泛成長策略的一部分，本公司亦正積極評估醫療保健及生命科學領域的其他戰略機會。這些機會可能包括收購、合作夥伴關係或其他戰略交易。無法保證任何此類舉措將最終促成交易完成。關於 Wellgistics Health, IncWellgistics Health 是一家快速擴張、以科技為驅動的醫療保健平台，定位於藥品分銷與患者獲藥管道的核心。本公司已建立一個涵蓋批發分銷、處方藥配送及人工智慧驅動的獲取解決方案的整合型高效能生態系統，直接串聯製藥廠商、醫療服務提供者及全國性的獨立藥局網絡。透過整合基礎設施、數據與智能自動化，Wellgistics 正執行一套資本效率高的營運模式，旨在於龐大且分散的醫療保健市場中搶佔顯著市佔率。本公司致力於拓展高毛利收入來源、深化與製造商的戰略合作關係，並在整個平台上推動營運槓桿效應。憑藉獨特的端到端服務方案與嚴謹的執行力，Wellgistics 已做好準備加速成長、提升獲利能見度，並為股東創造超乎預期的長期價值。關於 Neuritek Therapeutics Inc.Neuritek Therapeutics Inc. 開發了一種基於生物機制的次世代療法，旨在治療創傷後壓力症候群（PTSD）的根本成因。Neuritek 首款上市療法為口服活性脂肪酸酰胺水解酶 1 型（FAAH1）抑制劑，該酶負責代謝內源性大麻素（AEA），亦是首個針對 PTSD 機制的治療方案。 該公司由威廉·哈普沃斯（William Hapworth）醫學博士創立，他不僅是臨床研究的先驅，更是一位擁有逾 30 年臨床經驗的執業精神科醫師。欲了解更多資訊，請造訪 www.neuritek.com ，或透過 LinkedIn 加入討論：neuritek-therapeutics-inc前瞻性陳述本新聞稿包含符合《1995年私人證券訴訟改革法案》及其他適用聯邦證券法定義義的前瞻性陳述。這些前瞻性陳述包括但不限於：關於潛在收購 Neuritek Therapeutics, Inc.（「Neuritek」）之陳述，包括任何交易的預期架構、估值、時程及完成可能性；意向書之初步且非約束性性質；任何此類交易可能帶來的戰略、營運及財務效益； 本公司協商並簽訂最終協議之能力；本公司取得任何必要融資之能力；任何被收購業務之整合；以及本公司的整體成長策略與未來表現。前瞻性陳述可透過諸如「可能」、「可能」、「將會」、「應」、「預期」、「預估」、「相信」、「意圖」、「計劃」、「預測」、「估計」、「潛在」、 「機會」、「目標」、「預測」、「持續」、「將」及類似表述。此等前瞻性陳述係基於當前預期、假設及估計，並受重大風險與不確定性影響，其中許多因素超出本公司控制範圍。可能導致實際結果與預期存在重大差異的重要因素包括但不限於：各方未能簽訂最終協議的風險；意向書被終止或未能促成交易完成的風險；擬議估值及交易條款具初步性質所帶來的不確定性（此等內容可能發生重大變更）；未能以可接受條款取得所需融資或完全無法取得融資的風險； 任何交易預期效益未能實現的風險；將以研究為導向的組織整合至本公司現有業務所伴隨的風險；藥品或治療產品的開發、測試、監管批准及商業化相關風險，包括可能出現不利的臨床結果或延誤；監管及合規風險；以及本公司不時向美國證券交易委員會提交的文件中所述的其他風險與不確定性。前瞻性陳述僅反映其作出當日的狀況，不應過度依賴此類陳述。除適用法律要求外，本公司無義務更新或修訂任何前瞻性陳述。Wellgistics 媒體與投資者聯絡資訊媒體： media@wellgisticshealth.com 投資者關係： IR@wellgisticshealth.com 消息來源：Wellgistics Health, Inc. Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Key Results Highlights:- Revenue Growth: 8.6% increase to approximately HK$1,813.8 million- Net Profit Increase: 3.5% rise to HK$318.1 million, driven by operational efficiency- Final Dividend: Proposed final dividend of HK7.0 cents per share, bringing total dividend for 2025 to HK14.0 cents per share, a 16.7% surge from HK12.0 cents in 2024- Net Cash & Cash Equivalents: HK$782.7 million (HK$557.2 million as at 31st December 2024)Regulatory Milestones:- NMPA Approval: Multi-dose Diquafosol Sodium Eye Drops approved in July 2025; multi-dose Sodium Hyaluronate Eye Drops approved in January 2026 for registration and commercialisation in the PRC- BLA Acceptance: Bevacizumab ophthalmic injection BLA accepted by NMPA in August 2025, marking a crucial regulatory milestoneBusiness Developments:- Exclusive Distribution (Seefunge): Exclusive distribution of Seefunge's Emedastine Difumarate and Oxybuprocaine Hydrochloride Eye Drops in the PRC- Exclusive Distribution (Osteopore): Exclusive distribution of Osteopore’s innovative dental, orthodontic and maxillofacial products in the PRC, Hong Kong and Macau.- Collaboration with Airdoc: Joint operation of Artificial Intelligence-based retinal businesses in the PRC- Strategic Collaboration with Kenvue: Promotion and marketing of Kenvue's consumer health products (Rhinocort(R), Motrin(R), Tylenol(R)) in the PRC.- International Innovation Accelerator: Signed MOU with Suzhou Industrial Park to launch cross-border life sciences accelerator.- First Overseas Market Entry: Beifushu(R) introduced to Singapore via Special Access Route at Singapore National Eye Centre.Intellectual Property and Market Presence:- Robust IP Portfolio: 121 patent certificates or authorisation letters, comprising 91 invention patents, 15 utility model patents and 15 design patents.- Extensive Distribution Network: Products available in over 14,600 hospitals and medical providers, and approximately 2,600 pharmaceutical stores across the PRCAwards and Recognition:- 2025 Top 500 Manufacturing Companies in Guangdong Province: Recognises industrial scale and comprehensive competitiveness- National Manufacturing Champion Enterprise: Affirms leading position in specialized biopharmaceutical segment- 2025 "Golden Kunpeng" China Financial Value Ranking – Most Valuable Listed Company for Investment: Highlights capital market recognition of growth potential- Participation at Asia-Pacific Academy of Ophthalmology Congress 2026: Showcasing key ophthalmology products and pipeline assets, strengthening engagement with regional eye care professionals and institutions.HONG KONG, Mar 23, 2026 - (ACN Newswire via SeaPRwire.com) - Essex Bio-Technology Limited (“Essex” and its subsidiary the “Group”, Stock Code: 1061.HK), a leading biologic Group that develops, manufactures and commercialises genetically engineered therapeutic recombinant bovine basic fibroblast growth factor (“rb-bFGF”), today announced robust annual results for the year ended 31st December 2025, with revenue up 8.6% to HK$ 1,813.8 million and net profit up 3.5% YoY to HK$318.1 million. The Group achieved multiple regulatory milestones and expanded its product portfolio through strategic collaborations, and Beifushu’s landmark entry into Singapore. These achievements underscore Essex's commitment to innovation and operational excellence, driving sustained revenue and profit growth.Diversified Growth Fueled by Flagship BiologicsThe Group achieved a consolidated turnover of approximately HK$1,813.8 million, with an increase of 8.6% as compared to approximately HK$1,669.8 million in 2024. Correspondingly, the Group’s profit increased by 3.5% to approximately HK$318.1 million as compared to approximately HK$307.2 million in 2024.The Beifushu(R) series and Beifuji(R) series, the Group’s flagship products drove growth, contributing 83.5% of turnover.The ophthalmology segment (“Ophthalmology”) recorded a turnover of HK$835.0 million, grew 8.2% year-on-year, led by Beifushu(R) unit-dose eye drops and supported by its preservative free design and expanding application scenarios, which cover multiple areas such as dry eye treatment and post-operative recovery, and contributions from Beifushu(R) eye gel, (Iodized Lecithin Capsules) and a range of unit-dose eye drops (Tobramycin, Levofloxacin, Sodium Hyaluronate, Moxifloxacin Hydrochloride and Diquafosol Sodium Eye Drops).The surgical segment (“Surgical”) turnover rose 1.8% year-on-year to HK$895.9 million, leveraging Beifuji’s broad clinical applications across multiple medical departments and strong market presence. It is also supported by numerous clinical guidelines and expert consensus, thereby laying a solid foundation for future indication expansion and sustained growth. In addition, Group Carisolv(R) dental caries removal gel, PELNACTM collagen-based artificial dermis and SCALGENTM double-layered artificial dermis had further strengthened and contributed to the Surgical business.Notably, Healthcare and Partner Services delivered a total turnover of approximately HK$82.9 million for the year ended 31st December 2025, representing a significant increase of 350% as compared to 2024. The growth was primarily driven by Dr. YaDian oral care products, online and offline healthcare services and CMO/CDMO services.Strengthening Financial Position and Shareholder ReturnsThe Group maintains a healthy financial position, with cash and cash equivalents of approximately HK$782.7 million as of 31st December 2025. Bank borrowings stand at HK$325.6 million, with a manageable repayment schedule over 5 years period. The Group’s gearing ratio is at 30.9% (2024: 28.8%), indicating disciplined financial management and ample liquidity.The Board is pleased to propose a final dividend of HK7.0 cents per ordinary share. Together with the interim dividend of HK7.0 cents per ordinary share, the total dividend for 2025 reaches HK14.0 cents, representing a notable year-on-year increase of 16.7% from HK12.0 cents in 2024, demonstrating the Group’s ongoing commitment to delivering greater returns to its shareholders.Broad Portfolio and Robust Pipeline Fuel Sustained GrowthThe Group’s business comprises three core segments: Ophthalmology, Surgical (wound care and healing) and Healthcare and Partner Services segment, with the Group’s six (6) flagship commercialised biologics, collectively referred to as the “bFGF Series”, which are marketed and sold in the PRC. Three of the bFGF Series were approved by NMPA as Category I drugs, and five are listed on the National Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance in the PRC.In addition, the Group offers a portfolio of commercialised preservative-free unit-dose eye drops, including Tobramycin, Levofloxacin, Sodium Hyaluronate, Moxifloxacin Hydrochloride and Diquafosol Sodium Eye Drops. The Group further expanded its ophthalmology franchise by obtaining NMPA approvals for the registration and commercialisation of multi-dose Diquafosol Sodium Eye Drops in July 2025 and multi-dose Sodium Hyaluronate Eye Drops in January 2026. The new launches target the PRC’s growing dry eye treatment market, complementing the Group’s Beifushu(R) ophthalmic repair series.As for the Surgical segment, the Group’s Carisolv(R) dental caries removal gel, Portable Ultraviolet Phototherapy Devices, PELNACTM collagen-based artificial dermis, SCALGENTM double-layered artificial dermis and Osteopore’s bioresorbable implants (Osteomesh(R) and Osteoplug(R)), are complementing the Group’s Beifuji(R) wound healing series.Strategic R&D Investment to Capture Emerging Market OpportunitiesThe Group is committed to pragmatically investing in new products and technologies to strengthen its product and R&D pipeline, with a mission to develop groundbreaking therapeutics that address unmet clinical and commercial needs. In 2025, total R&D expenditures were approximately HK$177.2 million, representing 9.8% of the turnover, of which approximately HK$139.3 million were capitalised.During the year, the Group’s Medical Scar Repair Gel obtained NMPA registration approval as a Class II medical device, expanding the Group’s footprint in the fast-growing high-end wound care and medical aesthetics markets, unlocking new growth drivers for long-term success.The global phase 3 clinical project of bevacizumab ophthalmic injection (EB12-20145P) has successfully completed patient enrolment across the PRC, Australia, European Union countries and the United States, with the last patient last visit was completed. A Biologics License Application (BLA) was accepted by NMPA in the PRC in August 2025.To amplify the Group’s presence in the Asia ophthalmic community and accelerate the market launch of new products, the Group participated in the 2026 Asia-Pacific Academy of Ophthalmology (APAO) Congress. The event provided a premium platform to showcase ophthalmic solutions, engage with regional clinical experts and partners, and build momentum for the rollout of its innovative ophthalmic products, reinforcing its global brand influence.The Group holds a total of 121 patent certificates or authorisation letters, comprising 91 invention patents, 15 utility model patents and 15 design patents.The Group currently has multiple R&D sites located in Zhuhai (PRC), Boston (United States), London (United Kingdom) and Singapore. These sites support the Group’s efforts to develop new therapeutics and recruit global talent.To date, the Group has 18 R&D programmes ranging from pre-clinical to clinical stages, with several ophthalmology programs currently in the clinical stage, specifically Bevacizumab intravitreal injection, SkQ1 eye drops and Cyclosporine eye dropsBroadening Commercial Reach Through Market Expansion and PartnershipsAs of 31st December 2025, the Group maintains an extensive network of 47 regional sales offices in the PRC and a strategic base in Singapore to facilitate market access into Southeast Asian countries. With a vast distribution network, the Group’s products are prescribed in more than 14,600 hospitals and medical providers, coupled with approximately 2,600 pharmaceutical stores, covering major cities throughout the PRC.During the year under review, the Group achieved multiple landmark breakthroughs in the PRC and overseas market expansion, unlocking new multi-dimensional growth momentum. In the overseas market, the Group’s flagship product Beifushu(R) was successfully introduced to Singapore via the Special Access Route at the Singapore National Eye Centre, marking the product’s first commercial launch beyond the PRC, and establishing a solid foothold to support the Group’s future expansion into Southeast Asia and global markets.In the PRC market, the Group entered into two landmark strategic partnerships during the year: a collaboration with global consumer health leader Kenvue, under which the Group will leverage its extensive nationwide commercial network in the PRC to carry out promotion, medical education and marketing for Kenvue’s selected consumer health products including Rhinocort(R) (Budesonide Nasal Spray), Motrin(R) (Ibuprofen Suspension/Drops), and Tylenol(R) (Paracetamol Drops/Suspension); and an exclusive distribution agreement for Osteopore’s innovative dental, orthodontic and maxillofacial products in the PRC, Hong Kong and Macau, marking a strategic entry into the high-potential stomatology market. The partnerships broaden the Group’s healthcare business footprint, delivering strong synergies with its existing ophthalmology and regenerative medicine lines.To drive sustainable growth and expansion for its current and future products, the Group has been investing relentlessly in enhancing its competitiveness and broadening its reach by expanding the clinical indications for its commercialised products, increasing patient access in lower-tier cities across the PRC, developing complementary sales channels, and nurturing the healthtech e-platform to enhance patient access.The Group’s second factory at Zhuhai Hi-Tech Industrial Park, with a gross floor area of about 58,000 square meters for R&D, manufacturing, office and dormitory, is expected to complete in the period of 2026 -2027.Mr. Patrick Ngiam, Chairman of Essex, said “2025 was a standout year with Beifushu’s landmark entry into Singapore, driving robust growth through flagship products, innovation-focused R&D, and strategic partnerships. Essex remains committed to addressing unmet needs and driving long-term growth.We will proactively and systematically recalibrate operating and distribution costs to mitigate the negative impact on FY26 profit from the increase of VAT from 3% to 13% without disrupting our focus on Group development plans.”About EssexBio (1061.HK)EssexBio is a bio-pharmaceutical company that develops, manufactures, and commercialises genetically engineered therapeutic b-bFGF, with six commercialised biologics currently marketed in China. Additionally, the Company has a diverse portfolio of commercialised preservative-free unit-dose eye drops, Shilishun (Iodized Lecithin Capsules) and others, which are principally prescribed for wound healing and diseases in Ophthalmology and Dermatology. These products are marketed and sold through approximately 14,600 hospitals, supported by the Company’s 47 regional offices in China. Leveraging its in-house R&D platform in growth factor and antibody technology, EssexBio maintains a robust pipeline of projects in various clinical stages, covering a wide range of fields and indications. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

關鍵業績摘要：- 收入增長：收入同比增長8.6%至約18.14億港元- 淨利潤提升：得益於運營效率，淨利潤增長3.5%至3.18億港元- 末期股息：擬派末期股息每股0.07港元，2025年全年股息達每股0.14港元，較2024年全年股息的每股0.12港元大幅增加16.7%- 現金及現金等價物：7.83億港元（2024年12月31日：5.57億港元）研發里程碑：- NMPA批准：多劑量地誇磷索鈉滴眼液於2025年7月獲批；多劑量玻璃酸鈉滴眼液於2026年1月獲批在中國註冊和商業化。- BLA受理：貝伐珠單抗眼內注射液的生物製品許可申請（BLA）於2025年8月獲NMPA受理，標誌著重要的監管里程碑。商業發展：- 獨家代理（視方極）：獲得浙江視方極富馬酸依美斯汀滴眼液、鹽酸奧布卡因滴眼液的獨家代理權。- 獨家代理（Osteopore）：獲得Osteopore創新的牙科、正畸及頜面產品在中國內地、香港及澳門的獨家代理權。- 與鷹瞳科技合作：在中國實現眼底AI業務的聯合運營。- 與科赴戰略合作：在中國推廣及營銷科赴的消費者健康產品（雷諾考特(R)、美林(R)、泰諾林(R)）。- 國際創新加速器：與蘇州工業園區簽訂戰略合作諒解備忘錄，推出國際創新加速器。- 首個海外市場准入：貝復舒(R)通過特別採用程序成功引入新加坡國家眼科中心。知識產權與市場佈局：- 強大的知識產權組合：持有合共121份專利證書或授權書，包括91項發明專利、15項實用新型專利及15項外觀專利。- 廣泛的銷售網絡：產品覆蓋中國內地超14,600家醫院和醫療機構以及約2,600家藥房。獎項與榮譽：- 2025年廣東省製造業企業500強：表彰產業規模及綜合競爭力- 國家級製造業單項冠軍企業：確認在專業生物製藥領域的領先地位- 2025「金鯤鵬」中國財經價值榜－最具投資價值上市公司：突顯資本市場對增長潛力的認可- 參與2026年亞太眼科學會大會：展示主要眼科產品及在研管線，加強與區域眼科專業人士及機構的聯繫。香港, 2026年3月23日 - (亞太商訊 via SeaPRwire.com) - 億勝生物科技有限公司（「億勝生物」及其附屬公司「集團」；股份代號：1061.HK），一家領先的生物製藥企業，專注於研發、生產和銷售基因工程藥物重組牛鹼性成纖維細胞生長因子（「rb-bFGF」），今日公佈截至2025年12月31日止的強勁年度業績。集團收入同比增長8.6%至18.14億港元，利潤同比增長3.5%至3.18億港元。年內，億勝生物達成了多項監管里程碑，並通過戰略合作擴大了產品組合，同時成功將貝復舒(R)引入新加坡。這些成就彰顯了億勝對創新和卓越運營的承諾，持續推動收入和利潤的增長勢頭。旗艦生物藥推動多元化增長集團實現綜合營業額約18.14億港元，較2024年的約16.70億港元增長8.6%。相應地，集團溢利較2024年的約3.07億港元增長3.5%至約3.18億港元。集團的旗艦產品貝復舒(R)系列及貝復濟(R)系列持續帶動增長，佔總營業額的83.5%。眼科分部錄得營業額8.35億港元，同比大幅增長8.2%。其中，單劑量貝復舒(R)滴眼液憑藉無防腐劑設計及應用場景的持續拓展（覆蓋乾眼症治療及術後修復等多元領域）實現強勁銷售增長，貝復舒(R)眼用凝膠、適麗順(R)（卵磷脂絡合碘膠囊）和一系列不含防腐劑單劑量滴眼液（包括妥布黴素、左氧氟沙星、玻璃酸鈉、鹽酸莫西沙星及地誇磷索鈉滴眼液）亦作出持續貢獻。外科分部實現營業額8.96億港元，增長1.8%，主要受惠於貝復濟(R)系列產品在多個臨床科室的廣泛應用及其穩固的市場地位。同時，貝復濟(R)系列產品已獲多項臨床指南及專家共識支持，為未來適應症拓展及持續增長奠定基礎。此外，集團的Carisolv(R)齲齒凝膠、皮耐克可吸收性敷料、適可健雙層人工真皮修復材料等產品進一步增強並促進了外科業務的發展。值得注意的是，醫療保健及夥伴服務於截至2025年12月31日止年度錄得總營業額約8,290萬港元，較2024年大幅增長350%。增長主要來源於伢典醫生口腔護理產品、線上及線下醫療保健服務及CMO/CDMO服務等。穩健的財務基礎和股東回報集團維持穩健的財務狀況。截至2025年12月31日，集團錄得現金及現金等價物約7.83億港元。銀行借貸為3.26億港元，將在未來五年內按計劃償還。集團的資產負債比率為30.9%（2024年：28.8%），反映出集團具備嚴謹的財務管理能力和充足的流動性。董事會欣然建議派發末期股息每股普通股0.07港元。連同中期股息每股普通股0.07港元，2025年全年股息達到0.14港元，較2024年全年股息的0.12港元同比顯著增長16.7%，以彰顯集團致力於為股東創造價值的承諾。廣泛的產品組合及強大的研發管線支持持續增長集團業務由三個核心分部組成：眼科、外科（創傷護理及修復）以及醫療保健及夥伴服務分部。集團擁有六種於中國市場銷售的商業化生物製劑，統稱「bFGF系列」。其中三種bFGF系列為國家藥品監督管理局（「NMPA」）批准的國家一類新藥，五種被列入中國國家基本醫療保險、工傷保險和生育保險藥品目錄。此外，集團提供一系列商業化的不含防腐劑單劑量滴眼液，包括妥布黴素、左氧氟沙星、玻璃酸鈉、鹽酸莫西沙星及地誇磷索鈉滴眼液。集團進一步拓展其眼科產品組合，分別於2025年7月及2026年1月獲得NMPA批准多劑量地誇磷索鈉滴眼液及多劑量玻璃酸鈉滴眼液在中國註冊和商業化。新獲批產品聚焦於中國不斷增長的幹眼治療市場，以補充集團的貝復舒(R)眼表修復系列產品。外科方面，集團的Carisolv(R)齲齒凝膠及伢典醫生口腔護理產品，以及一系列產品及醫療器械（包括紫外線光療儀、皮耐克可吸收性敷料、Osteopore用於牙科手術的生物可吸收植入物（Osteomesh(R)及Osteoplug(R)）及其他用於近視防控的醫療器械），共同補充了集團的貝復濟(R)創傷修復系列產品。戰略性研發投資以把握新興市場機遇集團致力於務實地投資新產品及技術，以強化其產品及研發管線，使命是開發解決未滿足的臨床及商業需求的突破性的療法。2025年，研發總支出約為1.77億港元，佔營業額的9.8%，其中約1.39億港元已資本化。年內，集團醫用疤痕修復凝膠獲批NMPA二類醫療器械註冊證，將集團業務拓展至快速增長的高端傷口護理及醫療美容市場，解鎖新增長動力以推動長期發展。貝伐珠單抗眼內注射液（EB12-20145P）的全球三期臨床項目已成功完成了在中國、澳大利亞、歐盟國家及美國的患者入組，最後一名患者已完成最後一次訪視。其生物製品許可申請（BLA）已於2025年8月獲中國NMPA受理。為提升集團在亞洲眼科領域的影響力，並加速新產品的市場推出，集團參與了2026年亞太眼科學會（APAO）大會。該會議提供了一個絕佳平台，用以展示眼科解決方案、與區域臨床專家和合作夥伴交流，並為集團創新眼科產品的推出積聚動能，從而提升全球品牌影響力。集團持有121份專利證書或授權書，包括91項發明專利、15項實用新型專利及15項外觀專利。集團目前於珠海（中國）、波士頓（美國）、倫敦（英國）及新加坡設立多個研發基地。這些基地為集團開發新療法和招募全球人才提供支援。截至目前，集團共有18項研發計劃處於臨床前至臨床階段，其中數項眼科項目處於臨床階段，具體包括貝伐珠單抗眼內注射液、SkQ1滴眼液及環孢素滴眼液。透過市場擴張與合作拓寬商業覆蓋截至2025年12月31日，集團於中國設有47間地區銷售辦事處，並於新加坡設有戰略基地，以促進其產品進入東南亞市場。憑藉龐大的分銷網絡，集團的治療產品在中國各地的逾14,600家醫院及醫療機構以及約2,600家藥房開具處方，覆蓋了中國各地的主要城市。回顧年內，集團在國內外市場擴張方面取得了多項里程碑式的突破，解鎖了多維度的新增長動力。在海外市場，集團的旗艦產品貝復舒(R)通過特別採用程序成功引入新加坡國家眼科中心，標誌著該產品首次進入中國以外地區，為集團未來進軍東南亞及全球市場奠定了堅實基礎。在國內，集團年內達成了兩項具里程碑意義的戰略合作：與全球消費者健康領導企業科赴合作，利用集團在中國廣泛的全國性商業網絡，對科赴精選的消費者健康產品（包括雷諾考特(R)、美林(R)及泰諾林(R)）進行推廣、學術教育及營銷；以及與Osteopore簽訂獨家分銷協議，在中國內地、香港及澳門分銷其創新的牙科、正畸及頜面產品，標誌著集團戰略性進軍高潛力的口腔科市場。這些合作拓寬了集團醫療保健業務的版圖，並與其現有的眼科及再生醫學業務產生強大的協同效應。為推動現有及未來產品的可持續增長和擴張，集團一直不懈地進行投資，通過擴大其商業化產品的臨床適應症、增加中國較低線城市的患者可及性、開發補充銷售渠道，以及培育醫療科技電子平台以增強患者可及性，來提高其競爭力並拓寬覆蓋範圍。集團位於珠海高新區科技創新海岸的第二間工廠，建築面積約58,000平方米，用作研發、生產、辦公及宿舍，預計將於2026或2027年間完工。億勝生物主席嚴名熾先生表示：「2025年對億勝來說是具有里程碑意義的一年，貝復舒(R)成功引入新加坡，集團亦依託其核心產品、創新研發及戰略合作，實現穩健增長。未來，億勝將繼續致力於滿足未被滿足的臨床需求，推動集團長期發展。我们將主動、系統性地優化運營及銷售成本，以缓解增值税由3%上调至13%对2026财年利润带来的不利影响，同时保證集團發展規劃的穩步推進。」關於億勝生物（股票代碼﹕1061.hk）億勝生物是一間專注於研發、生產和銷售基因工程藥物b-bFGF的生物製藥企業，擁有包括貝復舒(R)、貝復濟(R)、貝復新(R)在內的六種基因工程藥物在中國上市銷售。此外，公司還擁有包含一系列不含防腐劑單劑量滴眼液和適麗順(R)卵磷脂絡合碘膠囊等的多元化產品組合，主要應用於眼科及皮膚科處方藥領域的創傷修復及疾病治療。這些產品在公司於中國的47個區域辦事處的支持下，在逾14,600家醫院進行營銷和銷售。依託自身在生長因子和抗體技術領域的研發平台，億勝生物在多個臨床階段擁有强大的項目管線，涵蓋廣泛的領域和適應症。網址: http://www.essexbio.com Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Brisbane, Australia--(ACN Newswire via SeaPRwire.com - March 23, 2026) - Graphene Manufacturing Group Ltd (TSXV: GMG) (OTCQX: GMGMF) ("GMG" or the "Company") is pleased to announce that the Company has officially launched its European sales activity. During the week of March 9th, GMG held a kick off training workshop in London where it brought together its new team members from various locations in Europe and UK for technical product and sales training.The GMG European Sales team numbers more than 10 professional sales executives based in Europe and UK who focus on lead generation, inside sales and executive sales business development for GMG's G® Lubricant and THERMAL-XR® products.Figure 1: Members of the GMG European Sales TeamTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/289529_gmg_figure1.jpgSeparately, the Company is also pleased to announce that it has been informed that the G® Lubricant patent in Europe has been accepted to be granted for a period of 20 years.Craig Nicol, CEO & Managing Director of the Company, commented "Building a sales force in key areas of the world is one of GMG's key activities it is focused on right now and to get the European team set up and running so fast has been a great achievement."Jack Perkowski, Chairman and Non-Executive Director of the Company, commented: "I congratulate the Company on building the European Sales team and look forward to hearing of future success."About GMG:GMG is an Australian based clean-technology company which develops, makes and sells energy saving and energy storage solutions, enabled by graphene manufactured via in house production process. GMG uses its own proprietary production process to decompose natural gas (i.e. methane) into its natural elements, carbon (as graphene), hydrogen and some residual hydrocarbon gases. This process produces high quality, low cost, scalable, 'tuneable' and low/no contaminant graphene suitable for use in clean-technology and other applications.The Company's present focus is to de-risk and develop commercial scale-up capabilities, and secure market applications. In the energy savings segment, GMG has initially focused on graphene enhanced heating, ventilation and air conditioning ("HVAC-R") coating (or energy-saving coating) which is now being marketed into other applications including electronic heat sinks, industrial process plants and data centres. Another product GMG has developed is the graphene lubricant additive focused on saving liquid fuels initially for diesel engines.In the energy storage segment, GMG and the University of Queensland are working collaboratively with financial support from the Australian Government to progress R&D and commercialization of graphene aluminium-ion batteries ("G+AI Batteries"). GMG has also developed a graphene additive slurry that is aimed at improving the performance of lithium-ion batteries.GMG's 4 critical business objectives are:Produce Graphene and improve/scale cell production processesBuild Revenue from Energy Savings ProductsDevelop Next-Generation BatteryDevelop Supply Chain, Partners & Project Execution CapabilityFor further information please contact:Craig Nicol, Chief Executive Officer & Managing Director of the Company at craig.nicol@graphenemg.com, +61 415 445 223Leo Karabelas at Focus Communications Investor Relations, leo@fcir.ca, +1 647 689 6041Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this news release.Cautionary Note Regarding Forward-Looking StatementsThis news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian and U.S. securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends", "believes" "expects" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or will "potentially" or "likely" occur. This information and these statements, referred to herein as "forward‐looking statements", are not historical facts, are made as of the date of this news release and include without limitation, the size, term and success of GMG's European sales team and the eventual granting of and successful enforceability of the Company's G® Lubricant patent.Such forward-looking statements are based on a number of assumptions of management, including the European sales team will perform and the Company's G® Lubricant patent will be patented successfully. Additionally, forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of GMG to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation that the GMG European Sales team does not successfully drive sales for the Company and the Company's G® Lubricant patent is not patented and the risk factors set out under the heading "Risk Factors" in the Company's annual information form dated November 4, 2025 available for review on the Company's profile at www.sedarplus.ca.Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/289529 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月23日 - (亞太商訊 via SeaPRwire.com) - 雲頂新耀宣佈與箕星藥業香港有限公司（以下簡稱「箕星藥業」）達成資產收購協議 (The Asset Purchase Agreement)，獲得艾曲帕米（Etripamil）鼻噴霧劑（擬定中文商品名：星必妥(R)）在大中華區的開發、商業化及產品地產化權益。此次合作是公司深化心血管領域戰略佈局的重要舉措，進一步豐富了公司的產品管線、增強協同效應，持續鞏固公司在心血管疾病領域的發展。根據協議，雲頂新耀將向箕星藥業支付3000萬美元（相當於約人民幣206,937,000元）首付款，以及最高不超過2000萬美元（相當於約人民幣137,958,000元）的開發裏程碑付款。作為本協議的一部分，雲頂新耀將獲得箕星藥業於2021年5月簽訂的許可協議及相關附屬協議項下的權利、權益、主張、職責、義務及責任（不包括雙方約定的部分除外責任）。艾曲帕米鼻噴霧劑是一款新型、速效的鈣離子通道阻滯劑，采用便攜式鼻噴霧劑給藥，起效迅速且耐受性良好，可居家自行使用，可及性高。該藥物於2025年12月獲得美國食品藥品監督管理局（FDA）批准（美國商品名：CARDAMYSTTM），成為30多年來首款且唯一獲批用於成人陣發性室上性心動過速（PSVT）急性症狀性發作的療法，開拓了PSVT治療新場景。患者可在無醫療監督的環境（如居家）自行給藥，實現對病情的主動掌控，使疾病管理從依賴急診幹預轉向更加主動的院外管理。此外，艾曲帕米鼻噴霧劑正開發用於伴有快速心室率反應的房顫（AFib-RVR）適應症，II期臨床研究已取得積極結果，並計劃推進III期臨床研究，未來有望進一步拓展至更廣泛患者人群。在中國，艾曲帕米鼻噴霧劑用於治療PSVT的新藥上市申請已於2025年1月17日獲中國國家藥品監督管理局（NMPA）正式受理，並預計於2026年第三季度獲批，有望為PSVT患者提供全新的治療選擇。PSVT是一種以突發突止為主要特征的心動過速臨床綜合征，發作時心率極快且節律規則，通常持續數分鐘至數小時，患者症狀明顯且恐懼感強。PSVT急性發作的治療缺乏安全、便捷、可在院外自行使用的快速終止藥物，使患者在發作期長期處於「被動等待」狀態，缺乏真正意義上的「按需自救」工具。據悉，在中國，每1000中約有2.3-4人患有PSVT，估計總患者人數為300-600萬。AFib-RVR的特征是心率不規則，紊亂且快速，呈漸進式發作且不易自行終止，容易反複持續。目前中國的房顫患病率1.6%，對應患者人數約2000萬，並隨老齡化加劇呈上升趨勢。PSVT與AFib-RVR都會增加患者的失控感和心理負擔。整體來看，PSVT及AFib-RVR患者人群規模超過2500萬人，臨床需求遠未得到滿足，亟需更便捷、更高效的治療選擇。臨床數據方面，此次艾曲帕米鼻噴霧劑獲中國NMPA新藥上市申請受理是基於艾曲帕米關鍵性III期 RAPID 研究和中國III期 JX02002 臨床研究所取得的數據結果。JX02002研究達到了方案預設的主要終點，治療期出現的不良事件（TEAEs）在艾曲帕米治療組和安慰劑組之間相當。艾曲帕米鼻噴霧劑獲FDA批准是基於一項紮實的臨床試驗項目所得出的結論，該項目共收集了來自超1,800名參與者、超2,000次PSVT發作的安全性數據。這包括成功的3期RAPID試驗，這是一項在全球範圍內開展的、隨機、雙盲、安慰劑對照研究，結果於2023年發表在《柳葉刀》雜志上。RAPID試驗達到了其主要終點：自行使用艾曲帕米的參與者（N=99）中有64%在30分鐘內從室上性心動過速轉為竇性心律，而安慰劑組（N=85）為31%（HR = 2.62; p